Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a proprietary droplet-based microfluidic screening workstation.


Biotechnology

Veraxa Biotech

Christoph Antz

Yasemin Doeger

Heinz Schwer Ph.D.

Marian Weiss

Anna Pryszlak

Torsten Bürgermeister

Edward A. Lemke

Steffen Runz

Paul F. Sauter

Christine Köhler

Michael Ruppert

Christoph A. Merten

Lars Hufnagel

The Research and Development team at Veraxa Biotech focuses on leveraging innovative methodologies to explore and enhance the capabilities of antibody screening. By integrating cutting-edge techniques in microfluidics and functional assessment, the team members—ranging from scientists to engineers—collaborate to identify and develop novel antibodies with therapeutic potential, thereby driving advancements in immunotherapy and biotechnology.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Veraxa Biotech

Leadership Team